ArticleInternational journal of clinical oncology2026

Efficacy, safety, and treatment feasibility of pembrolizumab plus lenvatinib in patients aged 75 years or older with advanced renal cell carcinoma: a Japanese multicenter retrospective study.

Shimpei Yamashita et al.PubMed ↗Publisher ↗

No numbers read from the abstract.